(Q53851211)

English

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer.

scientific article published in August 2005

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Kim N Chi

1

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

Stephen K Chia

2

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

Ross Dixon

3

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

Michael J Newman

4

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

Vince J Wacher

5

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

Branimir Sikic

6

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

Karen A Gelmon

7

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

publication date

1 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

23

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

4

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

311-315

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues

1 reference

https://api.crossref.org/works/10.1007%2FS10637-005-1439-X

21 January 2018

Variability in human cytochrome P450 paclitaxel metabolism

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multidrug resistance: molecular mechanisms and clinical relevance

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacologic approaches to reversing multidrug resistance.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16012790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-005-1439-X

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 May 2018

http://europepmc.org/abstract/MED/16012790

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53851211&oldid=2212308533"